Advertisement

Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease

      Abstract

      Background

      Direct oral anticoagulants (DOAC) are at least non-inferior to warfarin in efficacy and safety among patients with nonvalvular atrial fibrillation. Limited evidence is available regarding outcomes for nonvalvular atrial fibrillation patients with coronary/peripheral artery disease.

      Methods

      Non-valvular atrial fibrillation patients aged ≥65 years diagnosed with coronary/peripheral artery disease in the US Medicare population, newly initiating DOACs (apixaban, rivaroxaban, dabigatran) or warfarin were selected from January 1, 2013 to September 30, 2015. Propensity score matching was used to compare DOACs vs warfarin. Cox proportional hazards models were used to estimate the risk of stroke/systemic embolism, major bleeding, and composite of stroke/myocardial infarction/all-cause mortality.

      Results

      There were 15,527 apixaban-warfarin, 6,962 dabigatran-warfarin, and 25,903 rivaroxaban-warfarin–matched pairs, with a mean follow-up of 5-6 months. Compared with warfarin, apixaban was associated with lower rates of stroke/systemic embolism (hazard ratio [HR] 0.48; 95% confidence interval [CI], 0.37-0.62), major bleeding (HR 0.66; 95% CI, 0.58-0.75), and stroke/myocardial infarction/all-cause mortality (HR 0.63; 95% CI, 0.58-0.69); dabigatran and rivaroxaban were associated with lower rates of stroke/myocardial infarction/all-cause mortality (HR 0.79; 95% CI, 0.70-0.90 and HR 0.87; 95% CI, 0.81-0.92, respectively). Rivaroxaban was associated with a lower rate of stroke/systemic embolism (HR 0.72; 95% CI, 0.60-0.89) and a higher rate of major bleeding (HR 1.14; 95% CI, 1.05-1.23) vs warfarin.

      Conclusions

      All DOACs were associated with lower stroke/myocardial infarction/all-cause mortality rates compared with warfarin; differences were observed in rates of stroke/systemic embolism and major bleeding. Findings from this observational analysis provide important insights about oral anticoagulation therapy among non-valvular atrial fibrillation patients with coronary/peripheral artery disease and may help physicians in the decision-making process when treating this high-risk group of patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wolf PA
        • Abbott RD
        • Kannel WB
        Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study.
        Arch Intern Med. 1987; 147: 1561-1564
        • Wolf PA
        • Abbott RD
        • Kannel WB
        Atrial fibrillation as an independent risk factor for stroke: The Framingham Study.
        Stroke. 1991; 22: 983-988
        • Crijns HJ
        • Van Gelder IC
        • Van Gilst WH
        • Hillege H
        • Gosselink AM
        • Lie KI
        Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
        Am J Cardiol. 1991; 68: 335-341
        • The AFFIRM Investigators
        Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study.
        Am Heart J. 2002; 143: 991-1001
        • Lip GY
        • Beevers DG
        ABC of atrial fibrillation. history, epidemiology, and importance of atrial fibrillation.
        BMJ. 1995; 311: 1361-1363
        • Krahn AD
        • Manfreda J
        • Tate RB
        • Mathewson FA
        • Cuddy TE
        The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.
        Am J Med. 1995; 98: 476-484
        • Hohnloser SH
        • Crijns HJ
        • van Eickels M
        • et al.
        Effect of dronedarone on cardiovascular events in atrial fibrillation.
        N Engl J Med. 2009; 360: 668-678
        • Violi F
        • Lip GY
        • Basili S
        Peripheral artery disease and atrial fibrillation: a potentially dangerous combination.
        Intern Emerg Med. 2011; 7: 213-218
        • Violi F
        • Daví G
        • Hiatt W
        • et al.
        Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation.
        J Am Coll Cardiol. 2013; 62: 2255-2256
        • Kralev S
        • Schneider K
        • Lang S
        • Süselbeck T
        • Borggrefe M
        Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography.
        PLoS One. 2011; 6: e24964
        • Benjamin EJ
        • Levy D
        • Vaziri SM
        • D'Agostino RB
        • Belanger AJ
        • Wolf PA
        Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.
        JAMA. 1994; 271: 840-844
        • Vedovati MC
        • Becattini C
        • Agnelli G
        Combined oral anticoagulants and antiplatelets: benefits and risks.
        Intern Emerg Med. 2010; 5: 281-290
        • Lin YS
        • Tung TH
        • Wang J
        • et al.
        Peripheral arterial disease and atrial fibrillation and risk of stroke, heart failure hospitalization and cardiovascular death: a nationwide cohort study.
        Int J Cardiol. 2016; 203: 204-211
        • Marte T
        • Saely CH
        • Schmid F
        • Koch L
        • Drexel H
        Effectiveness of atrial fibrillation as an independent predictor of death and coronary events in patients having coronary angiography.
        Am J Cardiol. 2009; 103: 36-40
        • Steffel J
        • Verhamme P
        • Potpara TS
        The 2018 European Heart Rhythm association practical guide on the use of non-vitamin K antagonist oral ainticoagulants in patients with atrial fibrillation.
        Eur Heart J. 2018; 39: 1330-1393
        • Connolly SJ
        • Ezekowitz MD
        • Yusuf S
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Patel MR
        • Mahaffey KW
        • Garg J
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger CB
        • Alexander JH
        • McMurray JJ
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Giugliano RP
        • Ruff CT
        • Braunwald E
        • et al.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Lip GY
        • Keshishian A
        • Kamble S
        • et al.
        Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. a propensity score matched analysis.
        Thromb Haemost. 2016; 116: 975-986
        • Villines TC
        • Schnee J
        • Fraeman K
        • et al.
        A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
        Thromb Haemost. 2015; 114: 1290-1298
        • Laliberté F
        • Cloutier M
        • Nelson WW
        • et al.
        Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
        Curr Med Res Opin. 2014; 30: 1317-1325
        • Yao X
        • Abraham NS
        • Sangaralingham LR
        • et al.
        Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation.
        J Am Heart Assoc. 2016; 5e003725
        • Bai Y
        • Shi XB
        • Ma CS
        • Lip GYH
        Meta-Analysis of effectiveness and safety of oral anticoagulants in atrial fibrillation with focus on apixaban.
        Am J Cardiol. 2017; 120: 1689-1695
        • Deitelzweig S
        • Farmer C
        • Luo X
        • et al.
        Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
        Curr Med Res Opin. 2017; 33: 1583-1594
        • Li XS
        • Deitelzweig S
        • Keshishian A
        • et al.
        Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. a propensity-matched analysis of 76,940 patients.
        Thromb Haemost. 2017; 117: 1072-1082
        • Jones WS
        • Hellkamp AS
        • Halperin J
        • et al.
        Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
        Eur Heart J. 2014; 35: 242-249
        • Hu PT
        • Lopes RD
        • Stevens SR
        • et al.
        Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation and peripheral artery disease: insights from the ARISTOTLE trial.
        J Am Heart Assoc. 2017; 6e004699
        • Bahit MC
        • Lopes RD
        • Wojdyla DM
        • et al.
        Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial.
        Int J Cardiol. 2013; 170: 215-220
        • Hohnloser SH
        • Oldgren J
        • Yang S
        • et al.
        Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
        Circulation. 2012; 125: 669-676
        • Health Insurance Portability and Accountability Act of 1996
        (Public Law 104-191, 104th Congress, US Department of Health and Human Services. Published August 21, 1996. Available at:)
        • Jensen PN
        • Johnson K
        • Floyd J
        • Heckbert SR
        • Carnahan R
        • Dublin S
        A systematic review of validated methods for identifying atrial fibrillation using administrative data.
        Pharmacoepidemiol Drug Saf. 2012; 21: 141-147
        • Birkmeyer NJ
        • Gu N
        • Baser O
        • Morris AM
        • Birkmeyer JD
        Socioeconomic status and surgical mortality in the elderly.
        Med Care. 2008; 46: 893-899
        • Diez Roux AV
        • Merkin SS
        • Arnett D
        • et al.
        Neighborhood of residence and incidence of coronary heart disease.
        N Engl J Med. 2001; 345: 99-106
        • Lip GYH
        • Nieuwlaat R
        • Pisters R
        • Lane DA
        • Crijns HJ
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Pisters R
        • Lane DA
        • Nieuwlaat R
        • de Vos CB
        • Crijns HJ
        • Lip GY
        A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
        Chest. 2010; 138: 1093-1100
        • Thigpen JL
        • Dillon C
        • Forster KB
        • et al.
        Validity of International Classification of Disease codes to identify ischaemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation.
        Circ Cardiovasc Qual Outcomes. 2015; 8: 8-14
        • Cunningham A
        • Stein CM
        • Chung CP
        • Daugherty JR
        • Smalley WE
        • Ray WA
        An automated database case definition for serious bleeding related to oral anticoagulant use.
        Pharmacoepidemiol Drug Saf. 2011; 20: 560-566
        • Saw J
        • Bhatt DL
        • Moliterno DJ
        • et al.
        The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.
        J Am Coll Cardiol. 2006; 48: 1567-1572
        • Collison T
        • Smith JM
        • Engel AM
        Peripheral vascular disease and outcomes following coronary artery bypass graft surgery.
        Arch Surg. 2006; 141: 1214-1218
        • Rosenbaum PR
        • Rubin DB
        The central role of the propensity score in observational studies for causal effects.
        Biometrika. 1983; 70: 41-55
        • Austin PC.
        The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments.
        Stat Med. 2014; 33: 1242-1258
        • Austin PC
        Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.
        Stat Med. 2009; 28: 3083-3107
        • Connolly SJ
        • Eikelboom JW
        • Bosch J
        • et al.
        Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
        Lancet. 2017 Nov 10; ([e-pub ahead of print])https://doi.org/10.1016/S0140-6736(17)32458-3
        • Freedman B
        • Lip GY
        "Unreal world" or "real world" data in oral anticoagulant treatment of atrial fibrillation.
        Thromb Haemost. 2016; 116: 587-589
        • Steinberg BA
        • Shrader P
        • Thomas L
        • et al.
        Off-label dosing of non-vitamin K antagonist oral anticoagulations and adverse outcomes: the ORBIT-AF II Registry.
        J Am Coll Cardiol. 2016; 68: 2597-2604

      Linked Article